Perspective Therapeutics (CATX) Liabilities and Shareholders Equity (2011 - 2026)

Perspective Therapeutics has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $392.0 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 26.16% year-over-year to $392.0 million; the TTM figure through Jun 2026 stood at $1.4 billion (down 0.56% YoY), while the FY2025 annual figure was $267.0 million, down 21.73% from the prior year.
• Liabilities and Shareholders Equity came in at $392.0 million for Q2 2026 at Perspective Therapeutics, down from $410.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $410.8 million in Q1 2026 to a low of $58.1 million in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $228.3 million, with a median of $272.6 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity jumped 253.93% in 2024 and slipped 24.63% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $58.1 million in 2022, then soared by 68.51% to $97.9 million in 2023, then surged by 248.45% to $341.1 million in 2024, then slipped by 21.73% to $267.0 million in 2025, then soared by 46.84% to $392.0 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $392.0 million in Q2 2026, $410.8 million in Q1 2026, and $267.0 million in Q4 2025.